Preliminary indications that BH3 mimetics may modulate NK cell attack have been provided by a recent report indicating that the Mcl-1 inhibitor maritoclax may cooperate with NK cells to kill leukemia cells [50]. The gene discussed is MCL1; the disease is leukemia.